Shalini Pandey

This paper develops a cell-based therapy that enables sustained, dose-tunable delivery of monoclonal antibodies through a single administration, demonstrating long-term efficacy and safety in preclinical models.

This study identifies GPRC6A as a key regulator of mTORC1 signaling and tau pathology in tauopathies, showing that targeting GPRC6A could reduce tau accumulation and related neurodegeneration.